Lilly Expands Insulin Affordability Options 

Press enter to search
Close search
Open Menu
08/24/2020

This article was provided and sponsored by Eli Lilly and Company 

Lilly has expanded its insulin affordability options for people with diabetes available through the Lilly Diabetes Solution Center. The Lilly Insulin Value Program allows anyone with commercial insurance, or without insurance, to fill their monthly prescription of Lilly insulin for $35. The savings card can be obtained by calling the Lilly Diabetes Solution Center at (833) 808-1234. The Solution Center is open 8 am to 8 pm (EDT) Monday through Friday. 

This program is the latest development in an effort by Lilly to offer the broadest suite of affordability solutions for people who need help affording their insulin, especially during the COVID-19 crisis. 

Lilly has also made available three non-branded insulin options with a 50 percent lower list price to help people who use government insurance and are unable to use the savings cards in our program. 

Non-branded versions of Humalog® Mix75/25™ KwikPen® (insulin lispro protamine and insulin lispro injectable suspension, 100 units/mL) and Humalog® Junior KwikPen® (insulin lispro injection, 100 units/mL) were added to the list of offerings in April 2020. These non-branded insulin options are identical to the branded insulins, with different packaging and a 50 percent lower list price of $265.20 for a package of five KwikPens. In addition, Lilly continues to offer Insulin Lispro Injection (100 units/mL), the non-branded version of Humalog U-100, at a 50 percent lower list price of $137.35 per vial and $265.20 for a package of five KwikPens. 

Pharmacists may substitute the branded versions with these non-branded insulins at the pharmacy counter if they provide a lower out-of-pocket cost. Because most insurance plans provide affordable copays that are much lower than the retail price for medicines on formulary, people may still experience a lower out-of-pocket cost with a branded version. Pharmacists can run a cost comparison to determine which Lilly option is the best cost-saving one for them. 

Any pharmacy that does not stock these non-branded insulins can place an order and expect delivery in 1-2 days. All major U.S. wholesalers are distributing these insulins. 

Combined, Humalog U-100, Humalog Mix75/25, and Humalog Junior KwikPen make up more than 90 percent of prescriptions written for a Lilly mealtime insulin. With non-branded versions of each available, the vast majority of people using a Humalog formulation will have an option that may reduce their out-of-pocket costs. 

Information about these affordability options is available by calling the Lilly Diabetes Solution Center at 833-808-1234, Monday-Friday 8 am to 8 pm (EDT). Representatives can help determine whether the Lilly Insulin Value Program, one of Lilly’s non-branded insulins or another affordability option is the best financial choice. 

Terms, conditions, and limitations apply to the co-pay cards. Not available to those patients with government insurance such as Medicaid, Medicare, Medicare Part D, TRICARE®/CHAMPUS, Medigap, DoD, or any State Patient or Pharmaceutical Assistance Program. 

INDICATIONS AND IMPORTANT SAFETY INFORMATION FOR HUMALOG BRAND OF INSULINS AND LILLY’S NON-BRANDED INSULIN LISPRO PRODUCTS 

Indications 

Humalog (100 units/mL and 200 units/mL) and Insulin Lispro Injection (100 units/mL) are indicated to improve glycemic control in adults and children with diabetes mellitus. Humalog Mix75/25, Humalog Mix50/50 (insulin lispro protamine and insulin lispro injectable suspension, 100 units/mL) and Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25 (100 units/mL) are indicated to improve glycemic control in patients with diabetes mellitus. 

Limitations of Use 

The proportions of rapid-acting and intermediate-acting insulins in Humalog Mix75/25, Humalog Mix50/50, and Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25 are fixed and do not allow for basal versus prandial dose adjustments. 

IMPORTANT SAFETY INFORMATION FOR HUMALOG BRAND OF INSULINS AND LILLY INSULIN INJECTABLE PRODUCTS 

• Contraindications

Humalog, Insulin Lispro Injection, Humalog Mix75/25, Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25, and Humalog Mix50/50 are contraindicated during episodes of hypoglycemia and in patients who are hypersensitive to these insulins or any of their excipients. 

• Warnings and Precautions

Never share a Humalog, Insulin Lispro Injection, Humalog Mix75/25, Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25, or Humalog Mix50/50 prefilled pen, cartridge, reusable pen compatible with Lilly 3 mL cartridges, or syringe between patients, even if the needle is changed. Patients using vials must never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens. 

Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen: Changes in insulin strength, manufacturer, type, injection site, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. Any changes in insulin regimen should be made cautiously under close medical supervision and the frequency of blood glucose monitoring should be increased. Due to reports of hyperglycemia and hypoglycemia, advise patients who have repeatedly injected into areas of lipodystrophy or localized cutaneous amyloidosis to change the injection site to unaffected areas and closely monitor blood glucose. For patients with type 2 diabetes, dosage adjustments of concomitant antidiabetic products may be needed. 

Hypoglycemia: Severe hypoglycemia may be life threatening and can cause seizures or death. Hypoglycemia is the most common adverse reaction of Humalog, Insulin Lispro Injection, Humalog Mix75/25, Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25, and Humalog Mix50/50. Monitor blood glucose and increase monitoring frequency with changes to insulin dosage, use with glucose-lowering medications, meal pattern, physical activity; in patients with renal or hepatic impairment; and in patients with hypoglycemia unawareness. 

Hypoglycemia Due to Medication Errors: Instruct patients to always check the insulin label before each injection to avoid medication errors. Humalog U-200 should not be transferred from the Humalog KwikPen to a syringe as overdose and severe hypoglycemia can occur. 

Hypersensitivity Reactions: Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with Humalog, Insulin Lispro Injection, Humalog Mix75/25, Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25, and Humalog Mix50/50. If hypersensitivity reactions occur, discontinue the use of insulin and treat per standard of care until signs and symptoms resolve. 

Hypokalemia: Hypokalemia may be life threatening. Insulins, including Humalog, Insulin Lispro Injection, Humalog Mix75/25, Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25, and Humalog Mix50/50, cause a shift in potassium from the extracellular to intracellular space possibly leading to hypokalemia, which, if untreated, may result in respiratory paralysis, ventricular arrhythmia, and death. Monitor potassium levels in patients at risk for hypokalemia (e.g., patients using potassium-lowering medications or medications sensitive to serum potassium concentrations). 

Fluid Retention and Heart Failure with Concomitant Use of PPAR-gamma Agonists: Thiazolidinediones (TZDs), which are PPAR-gamma agonists, can cause dose-related fluid retention, particularly when used in combination with insulin, including Humalog, Insulin Lispro Injection, Humalog Mix75/25, Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25, and Humalog Mix50/50. This may lead to or exacerbate heart failure. Observe patients for signs and symptoms of heart failure and consider discontinuation or dose reduction of the PPAR-gamma agonist. 

Hyperglycemia and Ketoacidosis Due to Insulin Pump Device Malfunction: Malfunction of the insulin pump device, infusion set, or insulin degradation can rapidly lead to hyperglycemia and ketoacidosis. Patients using subcutaneous insulin infusion pumps must be trained to administer insulin by injection and have alternate insulin therapy available in case of pump failure. 

• Adverse Reactions

Adverse reactions associated with Humalog, Insulin Lispro Injection, Humalog Mix75/25, Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25, and Humalog Mix50/50 include hypoglycemia, hypokalemia, allergic reactions, injection-site reactions, lipodystrophy, pruritus, rash, weight gain, and peripheral edema. 

• Drug Interactions

Some medications may alter glucose metabolism, insulin requirements, and the risk for hypoglycemia or hyperglycemia. Signs of hypoglycemia may be reduced or absent in patients taking anti-adrenergic drugs. Particularly close monitoring may be required. 

Click to access Humalog Full Prescribing Information, Insulin Lispro Injection Full Prescribing Information, Humalog Mix75/25 Full Prescribing Information, Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25 Full Prescribing Information and Humalog Mix50/50 Full Prescribing Information

HI BOI SP U100 75/25 HCP ISI 10JAN2020 

Humalog®, KwikPen®, Humalog® Mix50/50TM, and Humalog® Mix75/25TM are trademarks or registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates. 

TRICARE® is a registered trademark owned by the U.S. Department of Defense. 

Related Topics